









Markets
/
Stocks
/
nasdaq-wve
/

WAVE Life Sciences Ltd

WVE

6.960USD

+0.160+2.35%

Close 09/18, 16:00（ET）Quotes delayed by 15 min

1.08BMarket Cap

LossP/E TTM



WAVE Life Sciences Ltd

6.960

+0.160+2.35%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated：2025-09-17

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite strong stock market performance and technicals, the fundamentals don't support the current trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

88 / 507

Overall Ranking

202 / 4723

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 15 analysts

Buy

Current Rating

19.800

Target Price

+190.32%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Wave Life Sciences Ltd. is a biotechnology company. The Company is focused on unlocking the potential of RNA medicines (oligonucleotides), or those targeting ribonucleic acid (RNA), to transform human health. Its RNA medicines platform, PRISMTM, combines multiple modalities, chemistry innovation and deep insights in human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. Its toolkit of RNA-targeting modalities includes RNA editing, splicing, antisense silencing and RNA interference (RNAi), providing Company with capabilities for designing and sustainably delivering candidates that optimally address disease biology. Its diversified pipeline includes clinical programs in Duchenne muscular dystrophy, Alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program in obesity. These programs include WVE-N531, WVE-006 and WVE-003. It is also building a pipeline of novel A-to-I RNA editing oligonucleotides (AIMers).

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 2867.99% year-on-year.

Fairly Valued

The company’s latest PE is -8.51, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 156.69M shares, decreasing 1.02% quarter-over-quarter.

Held by Lee Ainslie

Star Investor Lee Ainslie holds 8.26M shares of this stock.

Financial Health

Currency: USD Updated：2025-09-17

The company's current financial score is 5.58, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is low. Its latest quarterly revenue reached 8.70M, representing a year-over-year decrease of 55.82%, while its net profit experienced a year-over-year decrease of 53.29%.

Score

Industry at a Glance

Previous score

5.58

Change



Financials

8.32

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.52

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.77

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

2.22

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.09

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated：2025-09-17

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -8.51, which is -58.45% below the recent high of -3.53 and -21.91% above the recent low of -10.37.

Score

Industry at a Glance

Previous score

2.00

Change

0.8

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 88/507

No Data

Earnings Forecast

Currency: USD Updated：2025-09-17

The company’s current earnings forecast score is 8.53, which is higher than the Biotechnology & Medical Research industry's average of 8.03. The average price target for WAVE Life Sciences Ltd is 19.00, with a high of 36.00 and a low of 9.00.

Score

Industry at a Glance

Previous score

8.53

Change

Support & Resistance

No Data

Analyst Rating

Based on 15 analysts

Buy

Current Rating

19.800

Target Price

+191.18%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

WAVE Life Sciences Ltd

WVE

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated：2025-09-17

The company’s current price momentum score is 6.56, which is higher than the Biotechnology & Medical Research industry's average of 6.32. Sideways: Currently, the stock price is trading between the resistance level at 9.33 and the support level at 5.51, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.54

Change

0.02

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.428

Sell

RSI(14)

31.869

Neutral

STOCH(KDJ)(9,3,3)

8.233

Oversold

ATR(14)

0.570

Low Volatility

CCI(14)

-74.437

Neutral

Williams %R

93.797

Oversold

TRIX(12,20)

-0.987

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(5)

Neutral(0)

Buy(1)

Indicators

Value

Direction

MA5

6.904

Buy

MA10

7.242

Sell

MA20

8.383

Sell

MA50

8.412

Sell

MA100

7.583

Sell

MA200

9.175

Sell

Institutional Confidence

Currency: USD Updated：2025-09-17

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 98.46%, representing a quarter-over-quarter decrease of 2.88%. The largest institutional shareholder is Lee Ainslie, holding a total of 8.26M shares, representing 5.19% of shares outstanding, with 3.88% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

RA Capital Management, LP

18.20M

GSK plc

16.78M

Adage Capital Management, L.P.

12.52M

+30.08%

BlackRock Institutional Trust Company, N.A.

8.21M

+2.50%

Maverick Capital, Ltd.

Star Investors

8.26M

+0.01%

Driehaus Capital Management, LLC

6.36M

-5.27%

Shin Nippon Biomedical Laboratories Ltd

5.71M

M28 Capital Management LP

5.66M

Emerald Advisers LLC

5.06M

-0.57%

T. Rowe Price Associates, Inc.

Star Investors

4.03M

-19.40%

Risk Assessment

Currency: USD Updated：2025-09-17

The company’s current risk assessment score is 3.11, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is -1.36. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.